De Bhailís et al. [75] in a review focused on the role of GLP1-RAs and SGLT-2 inhibitors in treating patients with DKD and clearly demonstrated that these agents should now be considered the first choice in combination with metformin in patients with diabetes and increased cardiovascular risk and/or reduced renal function, in preference to other classes such as DPP-4 inhibitors or sulphonylureas. The gene discussed is GLP1R; the disease is diabetic kidney disease.